MDXH (MDxHealth) E10: $-1.77 (As of Mar. 2026)


MDXH MDxHealth SA MDXH
45 GF Score
Price $0.44
GF Value $2.20
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is MDxHealth E10?

MDxHealth MDXH -6.12% 45 E10 is $-1.77 as of Mar. 2026. GuruFocus rates MDXH with a GF Score™ of 45/100 and a GF Value™ of $2.20 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

MDxHealth's adjusted earnings per share data for the three months ended in Mar. 2026 was $-0.170. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.77 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-27), MDxHealth's current stock price is $0.4441. MDxHealth's E10 for the quarter that ended in Mar. 2026 was $-1.77. MDxHealth's Shiller PE Ratio of today is .


MDxHealth  (NAS:MDXH) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


MDxHealth E10 Related Terms


MDxHealth E10 Historical Data

* Premium members only.

The historical data trend for MDxHealth's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MDxHealth E10 Chart

MDxHealth Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -2.11 -1.83

MDxHealth Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.05 -1.95 -1.87 -1.83 -1.77

MDXH vs PRPO, BIOQ, IDXG: E10 Comparison

For the Diagnostics & Research subindustry, MDxHealth's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MDxHealth Shiller PE Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, MDxHealth's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where MDxHealth's Shiller PE Ratio falls into.


MDXH
45GF Score
MDxHealth SA MDXH
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MDxHealth E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, MDxHealth's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.17/135.0710*135.0710
=-0.170

Current CPI (Mar. 2026) = 135.0710.

MDxHealth Quarterly Data

per share eps CPI Adj_EPS
201106 0.000 95.508 0.000
201112 0.000 96.360 0.000
201206 0.000 97.659 0.000
201212 0.000 98.511 0.000
201306 0.000 99.215 0.000
201312 0.000 99.462 0.000
201406 0.000 99.482 0.000
201412 0.000 99.086 0.000
201506 0.000 100.107 0.000
201512 0.000 100.572 0.000
201606 0.000 102.267 0.000
201612 0.000 102.614 0.000
201706 0.000 103.902 0.000
201712 0.000 104.804 0.000
201806 0.000 106.063 0.000
201812 0.000 107.252 0.000
201906 0.000 107.896 0.000
201912 0.000 108.065 0.000
202006 0.000 108.540 0.000
202012 0.000 108.511 0.000
202106 0.000 110.305 0.000
202109 -0.600 111.543 -0.727
202112 -0.580 114.705 -0.683
202203 -0.500 118.620 -0.569
202206 -0.700 120.948 -0.782
202209 -0.800 124.120 -0.871
202212 -0.780 126.578 -0.832
202303 -0.530 126.528 -0.566
202306 -0.380 125.973 -0.407
202309 -0.370 127.083 -0.393
202312 -0.390 128.292 -0.411
202403 -0.310 130.552 -0.321
202406 -0.420 130.691 -0.434
202409 -0.400 130.968 -0.413
202412 -0.140 132.346 -0.143
202503 -0.190 134.348 -0.191
202506 -0.140 133.495 -0.142
202509 -0.160 133.743 -0.162
202512 -0.170 135.071 -0.170
202603 -0.170 135.071 -0.170

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-1.77 mean?
MDxHealth (MDXH) has a E10 of $-1.77 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on MDxHealth and its competitors.
Is MDxHealth's E10 too high?
MDxHealth's current E10 is $-1.77. Overall, MDxHealth has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MDxHealth's E10 compare to PRPO and BIOQ?
MDxHealth's E10 of $-1.77 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Medical Diagnostics & Research company?
A good E10 depends on the Medical Diagnostics & Research industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on MDxHealth and its competitors. MDxHealth's current E10 is $-1.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MDxHealth stock overvalued right now?
Based on GuruFocus' analysis, MDxHealth (MDXH) is currently considered Possible Value Trap. The stock's GF Value™ is $2.20, compared to a current price of $0.44 — trading 79.8% below its estimated fair value. The current E10 is $-1.77. MDxHealth's overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For MDxHealth (MDXH), the current E10 is $-1.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MDxHealth (MDXH) Overvalued in 2026?

Based on GuruFocus' analysis, MDxHealth stock appears to be undervalued. The current stock price of $0.44 is trading 79.8% below its estimated GF Value™ of $2.20. GuruFocus considers MDxHealth to be Possible Value Trap.

Key valuation signals for MDXH:

  • E10: $-1.77
  • GF Value™: $2.20 vs. price of $0.44 (79.8% below fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the MDXH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MDxHealth Business Description

Other Exchanges O6C1:Germany
Address Zone Industrielle des Hauts-Sarts, Rue d’Abhooz, 31, Cap Business Center, Herstal, Liege, BEL, 4040
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
45GF Score

Get the complete analysis for MDXH

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.44
Price
$2.20
GF Value